APLTApplied Therapeutics Inc.

Nasdaq www.appliedtherapeutics.com


$ 6.79 $ -0.05 (-0.73 %)    

Thursday, 28-Mar-2024 15:59:32 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 6.8
$ 7.09
$ 6.78 x 400
$ 6.80 x 400
$ 6.77 - $ 7.09
$ 0.76 - $ 9.39
1,560,770
na
572.86M
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-06-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-18-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-13-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 06-21-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 applied-therapeutics-says-fda-has-extended-review-period-for-nda-for-govorestat-at-007-for-treatment-of-classic-galactosemia-by-three-months-pdufa-target-action-date-november-28-2024

The FDA notified Applied Therapeutics that it required additional time to review supplemental analyses of previously submitted ...

 rbc-capital-initiates-coverage-on-applied-therapeutics-with-outperform-rating-announces-price-target-of-12

RBC Capital analyst Brian Abrahams initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating and ann...

 applied-therapeutics-files-prospectus-for-disposition-from-time-to-time-by-selling-stockholders-of-up-to-143m-shares-of-common-stock

-SEC Filing

 ubs-maintains-buy-on-applied-therapeutics-raises-price-target-to-13

UBS analyst Esther Rajavelu maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from $12 to ...

 eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

 ubs-maintains-buy-on-applied-therapeutics-raises-price-target-to-12

UBS analyst Esther Rajavelu maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from $4 to $12.

 applied-therapeutics-fy-eps-142-beats-144-estimate-sales-999m-miss-1067m-estimate

Applied Therapeutics (NASDAQ:APLT) reported quarterly losses of $(1.42) per share which beat the analyst consensus estimate of ...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

 advance-auto-parts-reports-q4-results-joins-bg-foods-vipshop-adt-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.

 fda-grants-review-date-for-applied-therapeutics-first-commercial-product-for-rare-metabolic-disorder

Applied Therapeutics surges as FDA grants Priority Review to govorestat (AT-007) for Galactosemia treatment. If approved, it wo...

 leerink-partners-initiates-coverage-on-applied-therapeutics-with-outperform-rating-announces-price-target-of-12

Leerink Partners analyst Joseph Schwartz initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating a...

 why-is-rare-disease-focused-applied-therapeutics-stock-trading-higher-today

Results of Applied Therapeutics' Phase 3 INSPIRE trial for oral govorestat (AT-007). Govorestat demonstrates significant so...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION